title: Effect of Antiepileptic drugs on plasma lipoprotein (a) and other lipid levels in childhood.
abstract: Antiepileptic drugs may alter plasma lipid status in epileptic patients. We conducted a study to assess the effect of phenobarbital, carbamazepine, and valproate on plasma levels of lipoprotein (a), total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein A, and apolipoprotein B in 22 epileptic children. The children were separated as group 1, seven children, mean age 1.6+/-0.2 years, treated with phenobarbital, 5 mg/kg/day, twice daily; group 2, seven children, mean age 9.8+/-1.2 years, treated with carbamazepine, 20 mg/kg/day, twice daily; and group 3, eight children, mean age 6.8+/-0.6 years, treated with valproate, 20 mg/kg/day, twice daily. Plasma lipoprotein (a) and other lipid levels were studied before (pretreatment) and at 3 and 6 months of treatment. Friedman two-way analysis of variance and Wilcoxon's signed-rank test were used for statistical analysis, and the results were expressed as the mean and standard error of the mean. The mean age of children in group 1 was significantly low, compared with groups 2 and, 3 (P < .001). The mean pretreatment lipid levels between the groups were not significant. The increase in lipoprotein (a) at 3 and 6 months and high-density lipoprotein cholesterol at 6 months was statistically significant in group 1 (P < .025). We suggest a careful monitoring of plasma levels of lipoprotein (a) and other lipids in epileptic children treated with antiepileptic drugs.
authors.affiliation: Department of Pediatric Neurology, Karadeniz Technical University, Trabzon, Turkey.
authors.forename: F M
authors.initials: FM
authors.lastname: Aynaci
authors.forename: F
authors.initials: F
authors.lastname: Orhan
authors.forename: A
authors.initials: A
authors.lastname: Orem
authors.forename: S
authors.initials: S
authors.lastname: Yildirmis
authors.forename: Y
authors.initials: Y
authors.lastname: Gedik
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D000927:Anticonvulsants / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D002220:Carbamazepine / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects*; D008297:Male; D010634:Phenobarbital / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014635:Valproic Acid / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D008076:Cholesterol, HDL; D008074:Lipoproteins; D014280:Triglycerides; D002220:Carbamazepine; D014635:Valproic Acid; D010634:Phenobarbital